Sign up for this week’s All Access giveaway here!
Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. ENLV, was a guest on Benzinga’s All Access on November 11, 2022.
Enlivex creates novel therapeutics for serious diseases like cancer, primarily through a process known as macrophage reprogramming. This innovative technology has led to the development of the company’s flagship product, Allocetra. The drug has shown very promising results in clinical trials thus far.
Watch the full interview here:
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
